PDF herunterladen
Hamostaseologie
DOI: 10.1055/a-2407-7914
Review Article

Update on Cancer-Associated Venous Thromboembolism in Children

Rahel Kasteler
1   Department of Oncology, Hematology, Immunology, Stem Cell Transplantation and Somatic Gene Therapy, University Children's Hospital Zurich - Eleonore Foundation, Zurich, Switzerland
2   Pediatric Hematology-Oncology Center, Children's Hospital of Eastern Switzerland, St Gallen, Switzerland
,
Manuela Albisetti
1   Department of Oncology, Hematology, Immunology, Stem Cell Transplantation and Somatic Gene Therapy, University Children's Hospital Zurich - Eleonore Foundation, Zurich, Switzerland
,
Alessandra Bosch
1   Department of Oncology, Hematology, Immunology, Stem Cell Transplantation and Somatic Gene Therapy, University Children's Hospital Zurich - Eleonore Foundation, Zurich, Switzerland
› Institutsangaben Funding Rahel Kasteler declares receiving a research grant from “SPOG Young Investigator Grant.” Alessandra Bosch declares receiving a research grant from “Claus Cramer Foundation.”
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Children with cancer have an increased risk for venous thromboembolic events (VTEs) compared to the healthy pediatric population. VTE rates in children with cancer vary among cancer types. Other VTE risk factors include central venous catheters and cancer therapies. VTE diagnosis relies on objective radiological imaging, and management to this date typically involves anticoagulant therapy. Low-molecular-weight heparins (LMWHs) are the most common choice. Evidence for primary VTE prevention is conflicting, and antithrombin replacement, LMWH, or apixaban have been studied. Recently, direct oral anticoagulants such as rivaroxaban or dabigatran were investigated for VTE treatment, showing promise in efficacy and safety. However, bleeding risks in this population need careful consideration, especially periprocedurally or with treatment-related thrombocytopenia. Prediction tools for VTE require adaptation for pediatric cancer patients. Progress in understanding and managing VTE in children with cancer is significant, with ongoing trials and real-world data contributing to improved strategies.

Zusammenfassung

Kinder mit malignen Erkrankungen haben im Vergleich zu gesunden Kindern ein erhöhtes Risiko für venöse thromboembolische Ereignisse (VTE). Die VTE-Raten variieren je nach Krebsart. Weitere VTE-Risikofaktoren sind zentrale Venenkatheter und Chemotherapien. Die VTE-Diagnose beruht auf einer objektiven radiologischen Bildgebung, und die Behandlung umfasst in der Regel eine Antikoagulation. Niedermolekulare Heparine (LMWH) sind die häufigste Wahl. Studienergebnisse zur VTE-Prävention sind widersprüchlich. Es wurden bisher Antithrombin-Substitutionen, LMWH oder zuletzt Apixaban untersucht. In jüngster Zeit wurden direkte orale Antikoagulanzien (DOAC) wie Rivaroxaban oder Dabigatran für die VTE-Behandlung untersucht, die vielversprechend in Bezug auf Wirksamkeit und Sicherheit sind. Blutungsrisiken in dieser Patientengruppe müssen jedoch sorgfältig bedacht werden, insbesondere peri-interventionell oder bei behandlungsbedingter Thrombozytopenie. Die Fortschritte für das Verständnis und für die Behandlung von VTE bei Kindern mit malignen Erkrankungen sind beträchtlich, wobei laufende Studien zu verbesserten Strategien beitragen.

Keywords

venous thromboembolism - childhood cancer - anticoagulants - primary prevention

Schlüsselwörter

venöse Thromboembolien - Pädiatrische maligne Erkrankungen - Antikoagulation - Primäre Prävention


Publikationsverlauf

Eingereicht: 17. Mai 2024

Angenommen: 27. August 2024

Artikel online veröffentlicht:
10. Dezember 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Tuckuviene R, Christensen AL, Helgestad J, Johnsen SP, Kristensen SR. Pediatric venous and arterial noncerebral thromboembolism in Denmark: a nationwide population-based study. J Pediatr 2011; 159 (04) 663-669
    CrossrefPubMedSuche in Google Scholar
  • 2 O'Brien SH, Stanek JR, Witmer CM, Raffini L. The continued rise of venous thromboembolism across US children's hospitals. Pediatrics 2022; 149 (03) e2021054649
    CrossrefPubMedSuche in Google Scholar
  • 3 Athale U, Siciliano S, Thabane L. et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 2008; 51 (06) 792-797
    CrossrefPubMedSuche in Google Scholar
  • 4 Prasca S, Carmona R, Ji L. et al. Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia. Thromb Res 2018; 165: 44-50
    CrossrefPubMedSuche in Google Scholar
  • 5 Athale UH, Mizrahi T, Laverdière C. et al. Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: a prospective evaluation. Pediatr Blood Cancer 2018; 65 (05) e26938
    CrossrefPubMedSuche in Google Scholar
  • 6 O'Brien SH, Klima J, Termuhlen AM, Kelleher KJ. Venous thromboembolism and adolescent and young adult oncology inpatients in US children's hospitals, 2001 to 2008. J Pediatr 2011; 159 (01) 133-137
    CrossrefPubMedSuche in Google Scholar
  • 7 Athale U, Cox S, Siciliano S, Chan AK. Thromboembolism in children with sarcoma. Pediatr Blood Cancer 2007; 49 (02) 171-176
    CrossrefPubMedSuche in Google Scholar
  • 8 Pelland-Marcotte MC, Pole JD, Kulkarni K. et al. Thromboembolism incidence and risk factors in children with cancer: a population-based cohort study. Thromb Haemost 2018; 118 (09) 1646-1655
    Thieme ConnectPubMedSuche in Google Scholar
  • 9 Jaffray J, Witmer C, O'Brien SH. et al. Peripherally inserted central catheters lead to a high risk of venous thromboembolism in children. Blood 2020; 135 (03) 220-226
    CrossrefPubMedSuche in Google Scholar
  • 10 Avila ML, Amiri N, Stanojevic S. et al. Can thrombophilia predict recurrent catheter-related deep vein thrombosis in children?. Blood 2018; 131 (24) 2712-2719
    CrossrefPubMedSuche in Google Scholar
  • 11 Andrew M, David M, Adams M. et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994; 83 (05) 1251-1257
    CrossrefPubMedSuche in Google Scholar
  • 12 van Ommen CH, Heijboer H, Büller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in the Netherlands. J Pediatr 2001; 139 (05) 676-681
    CrossrefPubMedSuche in Google Scholar
  • 13 van Ommen CH, Heijboer H, van den Dool EJ, Hutten BA, Peters M. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost 2003; 1 (12) 2516-2522
    CrossrefPubMedSuche in Google Scholar
  • 14 Spavor M, Halton J, Dietrich K. et al. Age at cancer diagnosis, non-O blood group and asparaginase therapy are independently associated with deep venous thrombosis in pediatric oncology patients: a risk model. Thromb Res 2016; 144: 27-31
    CrossrefPubMedSuche in Google Scholar
  • 15 De Stefano V, Za T, Ciminello A, Betti S, Rossi E. Haemostatic alterations induced by treatment with asparaginases and clinical consequences. Thromb Haemost 2015; 113 (02) 247-261
    Thieme ConnectPubMedSuche in Google Scholar
  • 16 Athale U. Thrombosis in pediatric cancer: identifying the risk factors to improve care. Expert Rev Hematol 2013; 6 (05) 599-609
    CrossrefPubMedSuche in Google Scholar
  • 17 Paz-Priel I, Long L, Helman LJ, Mackall CL, Wayne AS. Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol 2007; 25 (12) 1519-1524
    CrossrefPubMedSuche in Google Scholar
  • 18 Bosch A, Brunsvig Jarvis K, Brandão LR. et al. The role of coagulation factors VIII, IX and XI in the prediction and mediation of recurrent thrombotic events in children with non-central venous catheter deep vein thrombosis. Thromb Res 2024; 236: 228-235
    CrossrefPubMedSuche in Google Scholar
  • 19 LaVasseur C, Neukam S, Kartika T, Samuelson Bannow B, Shatzel J, DeLoughery TG. Hormonal therapies and venous thrombosis: Considerations for prevention and management. Res Pract Thromb Haemost 2022; 6 (06) e12763
    CrossrefPubMedSuche in Google Scholar
  • 20 Newall F, Branchford B, Male C. Anticoagulant prophylaxis and therapy in children: current challenges and emerging issues. J Thromb Haemost 2018; 16 (02) 196-208
    CrossrefPubMedSuche in Google Scholar
  • 21 Betensky M, Kulkarni K, Rizzi M. et al. Recommendations for standardized definitions, clinical assessment, and future research in pediatric clinically unsuspected venous thromboembolism: communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis. J Thromb Haemost 2022; 20 (07) 1729-1734
    CrossrefPubMedSuche in Google Scholar
  • 22 Ross C, Kumar R, Pelland-Marcotte MC. et al. Acute management of high-risk and intermediate-risk pulmonary embolism in children: a review. Chest 2022; 161 (03) 791-802
    CrossrefPubMedSuche in Google Scholar
  • 23 Avila L, Amiri N, De R. et al. Characteristics of upper- and lower-extremity deep vein thrombosis and predictors of postthrombotic syndrome in children. Blood Adv 2021; 5 (19) 3737-3747
    PubMedSuche in Google Scholar
  • 24 Whitworth H, Amankwah EK, Betensky M. et al. Updated guidance for efficacy and safety outcomes for clinical trials in venous thromboembolism in children: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis. J Thromb Haemost 2023; 21 (06) 1666-1673
    CrossrefPubMedSuche in Google Scholar
  • 25 Albisetti M, Kellenberger CJ, Bergsträsser E. et al. Port-a-cath-related thrombosis and postthrombotic syndrome in pediatric oncology patients. J Pediatr 2013; 163 (05) 1340-1346
    CrossrefPubMedSuche in Google Scholar
  • 26 Kuhle S, Spavor M, Massicotte P. et al. Prevalence of post-thrombotic syndrome following asymptomatic thrombosis in survivors of acute lymphoblastic leukemia. J Thromb Haemost 2008; 6 (04) 589-594
    CrossrefPubMedSuche in Google Scholar
  • 27 Monagle P, Cuello CA, Augustine C. et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv 2018; 2 (22) 3292-3316
    CrossrefPubMedSuche in Google Scholar
  • 28 Monagle P, Chan AKC, Goldenberg NA. et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (02) e737S-e801S
    CrossrefPubMedSuche in Google Scholar
  • 29 Goldenberg NA, Kittelson JM, Abshire TC. et al; Kids-DOTT Trial Investigators and the ATLAS Group. Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous thromboembolism: the Kids-DOTT randomized clinical trial. JAMA 2022; 327 (02) 129-137
    CrossrefPubMedSuche in Google Scholar
  • 30 Mitchell L, Andrew M, Hanna K. et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003; 90 (02) 235-244
    PubMedSuche in Google Scholar
  • 31 Greiner J, Schrappe M, Claviez A. et al; THROMBOTECT Study Investigators. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica 2019; 104 (04) 756-765
    CrossrefPubMedSuche in Google Scholar
  • 32 Pelland-Marcotte MC, Tole S, Pechlivanoglou P, Brandão LR. Effectiveness and safety of primary thromboprophylaxis in children with cancer: a systematic review of the literature and network meta-analysis. Thromb Haemost 2019; 119 (12) 2034-2042
    Thieme ConnectPubMedSuche in Google Scholar
  • 33 Albisetti M. Use of direct oral anticoagulants in children and adolescents. Hamostaseologie 2020; 40 (01) 64-73
    Thieme ConnectPubMedSuche in Google Scholar
  • 34 Palumbo JS, Lensing AWA, Brandão LR. et al. Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr. Blood Adv 2022; 6 (22) 5821-5828
    CrossrefPubMedSuche in Google Scholar
  • 35 Halton J, Brandão LR, Luciani M. et al; DIVERSITY Trial Investigators. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol 2021; 8 (01) e22-e33
    CrossrefPubMedSuche in Google Scholar
  • 36 Squibb B-M. NCT02464969 - Apixaban for the Acute Treatment of Venous Thromboembolism in Children 2015. Accessed September 5, 2024 at: https://clinicaltrials.gov/study/NCT02464969
    PubMed
  • 37 Daiichi S. NCT02798471- Hokusai Study in Pediatric Patients with Confirmed Venous Thromboembolism. 2017 . Accessed September 5, 2024 at: https://clinicaltrials.gov/study/NCT02798471
    PubMedSuche in Google Scholar
  • 38 O'Brien SH, Rodriguez V, Lew G. et al; PREVAPIX-ALL Investigators. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial. Lancet Haematol 2024; 11 (01) e27-e37
    CrossrefPubMedSuche in Google Scholar
  • 39 Rodriguez V, O'Brien S, Lew G. et al. Apixaban is effective and safe in reducing venous thromboembolism (VTE) in obese patients with newly diagnosed pediatric acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL) a sub-study analysis of the Prevapix-ALL/Children's Oncology Group ACCL1333 Trial. Blood 2023; 142 (Suppl. 01) 810
    CrossrefPubMedSuche in Google Scholar
  • 40 Bhatt MD, Parmar N, Fowler JA, Chan AKC, Athale UH. Feasibility and safety of delivering full-dose anticoagulation therapy in children treated according to Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium therapy protocols. Pediatr Blood Cancer 2019; 66 (02) e27483
    CrossrefPubMedSuche in Google Scholar
  • 41 Thrombosis Canada. Cancer and Thrombosis. 2023 . Accessed September 5, 2024 at: https://thrombosiscanada.ca/hcp/practice/clinical_guides?language=en-ca&guideID=CANCERANDTHROMBOSIS
    PubMedSuche in Google Scholar
  • 42 Douketis JD, Spyropoulos AC, Duncan J. et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med 2019; 179 (11) 1469-1478
    CrossrefPubMedSuche in Google Scholar
  • 43 Vidal E, Sharathkumar A, Glover J, Faustino EV. Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis. J Thromb Haemost 2014; 12 (07) 1096-1109
    CrossrefPubMedSuche in Google Scholar
  • 44 Klaassen ILM, Lauw MN, van de Wetering MD. et al. TropicALL study: Thromboprophylaxis in children treated for acute lymphoblastic leukemia with low-molecular-weight heparin: a multicenter randomized controlled trial. BMC Pediatr 2017; 17 (01) 122
    CrossrefPubMedSuche in Google Scholar
  • 45 Clark HH, Ballester L, Whitworth H, Raffini L, Witmer C. Prevention of recurrent thrombotic events in children with central venous catheter-associated venous thrombosis. Blood 2022; 139 (03) 452-460
    CrossrefPubMedSuche in Google Scholar
  • 46 Brandão LR, Albisetti M, Halton J. et al; DIVERSITY Study Investigators. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood 2020; 135 (07) 491-504
    CrossrefPubMedSuche in Google Scholar
  • 47 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
    CrossrefPubMedSuche in Google Scholar
  • 48 Mitchell L, Lambers M, Flege S. et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood 2010; 115 (24) 4999-5004
    CrossrefPubMedSuche in Google Scholar
  • 49 Betticher C, Bertaggia Calderara D, Matthey-Guirao E. et al. Global coagulation assays detect an early prothrombotic state in children with acute lymphoblastic leukemia. J Thromb Haemost 2024; 22 (09) 2482-2494
    CrossrefPubMedSuche in Google Scholar
  • 50 Bolek H, Ürün Y. Cancer-associated thrombosis and drug-drug interactions of antithrombotic and antineoplastic agents. Cancer 2023; 129 (20) 3216-3229
    CrossrefPubMedSuche in Google Scholar
  • 51 van Ommen CH, Albisetti M, Bhatt M, Bonduel M, Branchford B, Chalmers E, Chan A, Goldenberg NA, Holzhauer S, Monagle P, Nowak-Göttl U, Revel-Vilk S, Sciuccatie G, Sirachainan N, Male C. Subcommittee on Pediatric, Neonatal Thrombosis, Hemostasis. International pediatric thrombosis network to advance pediatric thrombosis research: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis. J Thromb Haemost 2021; 19 (04) 1123-1129 . PMID: 33792176; PMCID: PMC8252713
    CrossrefPubMedSuche in Google Scholar